Our first investigational cardiac regenerative medicine consists of iMP cells. iMP cells are designed to treat patients with ischaemic heart disease – ischaemic cardiomyopathy – undergoing coronary artery bypass graft (CABG). They are injected around cardiac scar tissue via a single application during bypass surgery.
We have successfully completed European Phase 2 trials using iMP cells as a cardiac-specific cellular medicine. Additional trials are set to begin in 2017. iMP cells have been designated as an advanced therapeutic medicinal product by the European Medicines Agency. A Phase 2 trial in Kawasaki disease is also planned.